SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced on July 2, 2025, that its Compensation Committee has granted inducement awards to seventeen new employees under the company's 2024 Inducement Plan. These awards include non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (RSUs). The stock options have an exercise price of $21.24 per share, reflecting Acadia's closing trading price on the grant date, and will vest over four years. The RSUs will also vest over four years, with specific vesting schedules tied to anniversaries of the grant date. These grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4) as part of the company's effort to incentivize its new employees.